Post-Trade Analysis: Ovid Therapeutics Inc (OVID) Climbs 11.27, Closing at 0.78

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $0.70 in the prior trading day, Ovid Therapeutics Inc (NASDAQ: OVID) closed at $0.78, up 11.27%. In other words, the price has increased by $11.27 from its previous closing price. On the day, 1.63 million shares were traded. OVID stock price reached its highest trading level at $0.78 during the session, while it also had its lowest trading level at $0.6903.


Our goal is to gain a better understanding of OVID by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.47 and its Current Ratio is at 10.47. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.57.

On April 30, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $9.

On April 29, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.H.C. Wainwright initiated its Buy rating on April 29, 2024, with a $9 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when LEVIN JEREMY M bought 18,248 shares for $2.76 per share. The transaction valued at 50,364 led to the insider holds 3,616,715 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OVID now has a Market Capitalization of 55336784 and an Enterprise Value of -19224190. For the stock, the TTM Price-to-Sale (P/S) ratio is 117.73 while its Price-to-Book (P/B) ratio in mrq is 0.71. Its current Enterprise Value per Revenue stands at -40.583 whereas that against EBITDA is 0.314.

Stock Price History:

The Beta on a monthly basis for OVID is 0.42, which has changed by -0.771261 over the last 52 weeks, in comparison to a change of 0.26238096 over the same period for the S&P500. Over the past 52 weeks, OVID has reached a high of $4.14, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is -73.81%, while the 200-Day Moving Average is calculated to be -76.39%.

Shares Statistics:

The stock has traded on average 591.70K shares per day over the past 3-months and 3130200 shares per day over the last 10 days, according to various share statistics. A total of 70.69M shares are outstanding, with a floating share count of 57.57M. Insiders hold about 18.85% of the company’s shares, while institutions hold 60.19% stake in the company. Shares short for OVID as of 1715731200 were 2850541 with a Short Ratio of 4.85, compared to 1713139200 on 2798057. Therefore, it implies a Short% of Shares Outstanding of 2850541 and a Short% of Float of 4.8800003.

Earnings Estimates

Ovid Therapeutics Inc (OVID) is currently under the scrutiny of 9.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.26, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.13 and low estimates of -$0.26.

Analysts are recommending an EPS of between -$0.56 and -$1.03 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.41, with 7.0 analysts recommending between $1.4 and -$0.85.

Revenue Estimates

A total of 8 analysts have provided revenue estimates for OVID’s current fiscal year. The highest revenue estimate was $740k, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $310k. In the same quarter a year ago, actual revenue was $392k

Most Popular